Evinacumab for children with homozygous familial hypercholesterolemia: a plain language summary
This Plain Language Summary of Publication article (PLSP) from Future Cardiology, explains the results of a study on evinacumab, a treatment for children with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder that prevents the liver from effectively removing “bad” cholesterol (LDL-C). High LDL-C levels increase the risk of early heart disease, and existing treatments for children with HoFH are limited. Evinacumab is approved in multiple countries as an add-on therapy for children aged 5 to 11 years and is also approved for HoFH treatment in Japan, Brazil, and Israel.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Evinacumab for Pediatric Patients WithHomozygous Familial Hypercholesterolemia’ and was published in the Circulation.
Visit AHA Journals using the link to read the original article.